Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT07924293
Active, not recruiting Observational

A Study to Evaluate the Acceptability of the FemBloc System as a Non-surgical, Permanent Contraceptive Method

NCT07924293 · tracked via the Priya Life Science Spain tracker
Sponsor
Femasys Inc
Phase
Observational
Started
2025-10-22
Last updated
2026-11-09

Condition(s) studied

Contraception

Investigational drug(s) / intervention(s)

FemBloc Permanent Birth Control

FemBloc Permanent Birth Control: Treatment for women who desire non-surgical permanent birth control by occlusion of the fallopian tubes.

Study summary

A Prospective Observational Pilot Study to Evaluate the Acceptability of the FemBloc System as a Non-surgical, Permanent Contraceptive Method in Spain

Eligibility

Sex
FEMALE
Min age
21 Years
Max age
49 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Women between 21 and 49 years old with a desire for permanent contraception * No desire for future motherhood * Capacity to give informed consent * Candidates for the FemBloc procedure according to medical assessment * Willing to continue using their alternative method of contraception until confirmation of occlusion * Women who have had the FemBloc procedure performed by clinical practice as of August 1, 2025, that meet all other inclusion and none of the exclusion criteria, and that have medical records collected with the necessary information for the study in order to comply with it Exclusion Criteria: * Previous tubal surgery * Ectopic pregnancy * Uterine malformations or difficulties in cervical canalization * Active or recent genital infection * Known hypersensitivity to the polymer or formaldehyde * Postpartum or abortion within the last 6 weeks * Undiagnosed abnormal uterine bleeding

Primary outcome measure(s)

  • Degree of patient satisfaction — At time of procedure
    To evaluate the acceptance of the FemBloc procedure in real life by female candidates by measuring the degree of satisfaction reported by participants on Likert scale (1-5, 5=highest satisfaction)

Trial sites (20)

FacilityCityRegionStatus
Hospital Universitario San Pedro Logroño La Rioja
Hospital Materno Infantil de Badajoz Badajoz Spain
Hospital Universitario de Cruces Barakaldo Spain
Hospital Universitario Basurto Bilbao Spain
Hospital Universitario de Burgos Burgos Spain
Hospital Universitario Reina Sofía Córdoba Spain
Hospital Universitario Virgen de las Nieves Granada Spain
Hospital Universitario Materno Infantil de Canarias Las Palmas de Gran Canaria Spain
Hospital Arnau de Vilanova Lleida Spain
Hospital Universitario La Paz Madrid Spain
Hospital Universitario Puerta De Hierro Majadahonda Spain
Hospital Universitario de Móstoles Móstoles Spain
Hospital Clínico Universitario de Salamanca Salamanca Spain
Hospital Universitario Donostia San Sebastián Spain
Hospital Universitario Infanta Sofía San Sebastián de los Reyes Spain
Hospital Universitario Marqués de Valdecilla Santander Spain
Hospital Universitario Virgen del Rocío Seville Spain
Hospital Universitario Virgen Macarena Seville Spain
Hospital Universitario y Politécnico La Fe Valencia Spain
Hospital Lozano Blesa Zaragoza Spain

Other trials for the same condition

Bone Metabolism in Premenopausal Exercising Women Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07924293 on ClinicalTrials.gov ↗ ← All trials in Spain